Price:
Rs. 10,000.00
Sample Type: Tissue
Fasting Not Required
Notes: C8869
Frequently Asked Questions (FAQ's):
What does the CDKN2A/2B Homozygous Gene Deletion test include?
This test identifies the complete deletion of CDKN2A/2B genes (P16) at chromosome 9p21.3, which may influence tumor progression and prognosis.
How does Metropolis Healthcare perform this test?
Metropolis Healthcare uses validated molecular or cytogenetic assays, such as FISH or PCR-based methods, to detect homozygous deletions accurately.
Who should take this test?
Patients with cancers, particularly hematologic malignancies or solid tumors where CDKN2A/2B deletion may impact prognosis or therapy, may be recommended this test.
What sample type is required?
The test can be performed on peripheral blood, bone marrow, or tumor tissue samples, depending on clinical context.
Why is detecting CDKN2A/2B deletion important?
Homozygous deletion of these tumor suppressor genes is linked to aggressive disease, poor prognosis, and may influence targeted treatment strategies.
How reliable are results from Metropolis Healthcare?
Metropolis Healthcare follows strict quality control, validated assays, and expert interpretation to ensure accurate and reproducible detection of gene deletions.
Is any preparation needed before the test?
No special preparation is generally required, but patients should follow sample collection instructions provided by their physician.
How soon are results available?
Turnaround time may vary depending on the method used, but Metropolis Healthcare provides timely reports to support clinical decision-making and treatment planning.